NYSE
$9.84▼ 1.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $613.3MShares out 62.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 3d agoAfter-hours26.10.22 05:074Ownership#●●●
Ginkgo Bioworks Holdings, Inc.
Insider Steven P. Coen of Ginkgo Bioworks Holdings, Inc. reported a change in beneficial ownership of securities as of October 16, 2026. This filing serves as the official Form 4 notification to the SEC regarding the insider's transaction.…more
$9.84-1.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:064Ownership
Ginkgo Bioworks Holdings, Inc.
Insider Barry Canton of Ginkgo Bioworks Holdings, Inc. reported changes in beneficial ownership of securities effective October 16, 2026. This filing is a standard Form 4 disclosure regarding executive stock transactions.…more
$9.84-1.35%vs prev closeView filingShare - 3d agoAfter-hours26.10.22 05:064Ownership
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. insider Reshma P. Shetty has filed a Form 4 statement regarding changes in beneficial ownership of securities as of October 16, 2026. This filing serves to provide transparency to the market regarding the insider's equity transactions.…more
$9.84-1.35%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Regular26.10.10 01:49#●●●#●●●
Glaukos Reports Successful Phase 4 Results for iDose TR Eye Therapy
Glaukos achieved its primary efficacy goals in a Phase 4 clinical trial, demonstrating superior intraocular pressure reduction when combining iDose TR with cataract surgery. The therapy offers a long-term solution to improve patient compliance compared to traditional daily eye drops.…more
$9.84-1.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.9Regular26.10.10 01:26
●●●●●●●● ●●●●● ●●●●●●
Ginkgo Bioworks announced a partnership with the National Science Foundation to provide remote laboratory infrastructure and integrated high-speed imaging tools into its autonomous facility. The news of government-backed research support and enhanced AI-driven lab capabilities triggered a significant rise in the company's stock price.…more
$9.84-1.35%vs prev closeShareBenzinga - 10.8After-hours26.10.09 05:22
●●●●●●●● ●●●●● ●●●●●●
Ginkgo Bioworks will provide autonomous lab access and protein testing services to support the NSF's $1.5 billion X-Labs initiative. This partnership facilitates remote research capabilities, though it lacks immediate financial impact data.…more
$9.84-1.35%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report